Joinn Laboratories (China) (HKG:6127, SHA:603127) expects a net profit attributable to shareholders of around 58.7 million yuan and 88.0 million yuan for 2024, representing a between 77.8% to 85.2% year-over-year decline.
The drug developer attributed the forecast to lower gross profit margins and the decrease in the market price of biological assets held by the company, a Friday Hong Kong bourse filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.